Podcasts about CSL

In this episode, Sarah interviews Vasudha, a UX Designer at Amazon AWS Applied AI, to talk about what it really looks like to invest in your career early, and how the impact compounds for years.Vasudha joined Career Strategy Lab's UX job search accelerator in late 2023 while finishing her master's degree, navigating the uncertainty of the job market as an international student, and waiting to see whether her AWS internship would convert to a full-time role. Today, she's thriving at Amazon, and still actively uses CSL frameworks for LinkedIn updates, internal promotions, and long-term career growth.This episode is a powerful reminder that Career Strategy Lab isn't just about landing one job. It's about building a career operating system you can reuse, refine, and rely on over time.What You'll Learn in This Episode:✔️ Why Vasudha decided to invest in CSL while still in grad school✔️ How talking to an alumni helped her decide to join✔️ Why CSL skills extend far beyond the job search✔️ How the portfolio sprint changed how she approaches real projects at Amazon✔️ Why answering “why” matters just as much as showing artifacts✔️ How CSL frameworks support promotions—not just hiring✔️ The confidence shift that comes from understanding your blind spots✔️ Why embracing being a UX generalist unlocked clarity and growth✔️ How CSL helps you tell the right story about yourself (not the wrong one)Timestamps:00:00 Introduction to Sarah Doody and Career Strategy Lab00:38 Episode Overview and Open House Context01:21 Vasudha's Journey: From Master's to Amazon05:38 The Impact of Career Strategy Lab10:56 Portfolio Development and Career Growth16:37 The Importance of Storytelling in UX Careers21:54 Advice for Joining Career Strategy Lab23:41 Conclusion and Final Thoughts

Kyle Sockwell has long branded himself as the “CEO of Fun,” but anyone who has worked with him behind the scenes knows that label only tells half the story. Sockwell, now the COO of the newly announced College Swimming League (CSL), has built a reputation in aquatic sports for something that's surprisingly rare in this industry: clarity. Behind the scenes, he's direct about what he knows and what he doesn't. Clear about what's possible and what isn't. And refreshingly uninterested in spin or “gotcha” communication. That matters when the topic is a massive structural shifts in college swimming. The CSL announcement dropped December 9th and immediately became one of the most discussed developments in our sport. The league named former International Swimming League (ISL) Toronto Titans GM Rob Kent as CEO, with Sockwell operating alongside him as COO. In this GMM podcast, we briefly cover Kyle's start and evolution in sports media, and then we dig into the details surrounding CSL

The demise of CBA & CSL's share prices, the Aussie miners surge, and corporate governance flares up again - Sean Aylmer, Michael Thompson and Adam Lang each nominate their top local corporate story from the year, and choose a winner. This is Fear & Greed's summer series - all-new short episodes every day, with regular news back from January 12.Find out more: https://fearandgreed.com.au/See omnystudio.com/listener for privacy information.

The demise of CBA & CSL's share prices, the Aussie miners surge, and corporate governance flares up again - Sean Aylmer, Michael Thompson and Adam Lang each nominate their top local corporate story from the year, and choose a winner. This is Fear & Greed's summer series - all-new short episodes every day, with regular news back from January 12.Support the show: http://fearandgreed.com.au/See omnystudio.com/listener for privacy information.

The ASX 200 kicked off the short week in fine style up 79 points (0.9%) to 8699 as gold and copper headed for records in Asia. Resource stocks kicked again, BHP up 1.6% with FMG up 1.7%. Gold miners in demand, NST up 4.1% and NEM up 5.2%. BGL was the only loser in the gold sector. Lithium stocks also ran, MIN up 6.2% and LTR pushed 5.5% better as it starts underground mining. Rare earths also doing ok. MEI jumped 32.1% om environmental approvals, LYC up 2.4%. Even uranium stocks glowed today, PDN up 7.0%. Banks were better with CBA up 0.3% and ANZ up 0.7%. The Big Bank Basket up to $275.41 (+0.2%). Healthcare firmed, CSL up 0.7% and PME rallied 2.3%. REITs modestly higher. Industrials mixed, WTC fell 4.2%, XRO flat. REA and CAR slightly better, retail was boosted by NCK up 9.9% on a trading update. APE also rallied hard up 6.3%.In corporate news, DRO soared 7.9% on new director guidelines on shareholdings. IGO jumped 2.6% on commissioning a new chemical plant at Greenbushes. NXT soared 6.6% on further contract wins.Nothing on the economic dance card.Asian markets were firm. Japan's Nikkei up 1.9%, China up 0.8% and HK up 0.2%.US futures – DJ up 33 Nasdaq up 9510-year yields steady at 4.80%.Want to invest with Marcus Today? Our MT20 portfolio is designed for investors seeking exposure to our strategy while we do the hard work for you. If you're looking for personal financial advice, our friends at Clime Investment Management can help. Their team of licensed advisers operates across most states, offering tailored financial planning services.  Why not sign up for a free trial? Gain access to expert insights, research, and analysis to become a better investor.

From fitness training to the Procar series, from high-performance models and the Batmobile BMW 3.0 CSL to the Art Cars. With unconventional ideas, Jochen Neerpasch propelled BMW Motorsport to the podium in the 1970s.

The ASX 200 started off the week down 62 points to 8635 (0.7%). Miners bore the brunt of the selling after a stellar week last week, with BHP down 2.9% and RIO falling 2.4% on lower iron ore and copper prices.  Gold miners too in profit taking mode after solid gains on Friday. GMD fell 5.4% and NEM off 0.9%. Lithium miners were also in profit taking mode as PLS fell 3.9% and LTR off 6.4%. Uranium stocks dropped hard as the AI trade in the US was called into question again, and thus the energy trade. NXG fell 4.5% and PDN down 4.7% with BOE off 8.2%. The banks were relatively calm as CBA fell 0.6% with the other three higher. The Big Bank Basket eased to $272.41 (-0.1%). Other financials eased, ASX under pressure following the ASIC reforms, GQG up 1.1% and SOL falling 1.2%. Insurers were generally better. Healthcare mixed as CSL stumbled 2.5% lower, TLX falling another 4.2%. REITs mixed, industrials mixed too. TLS down 0.8% and TPG up 1.8% with tech trying to find a base, WTC down 0.7% and XRO up 0.6%. The All-Tech Index up 0.04%. Retailers also found some bargain hunters, JBH up 2.3% and APE recovering 1.0%. In corporate news, TWE in a trading halt pending outlook statement. EOS jumped 28.9% on an US$80m order from South Korea. 4DX rose 9.9% on news of approvals in Canada. WGX announced plans to spin off non-core assets and FMG announced plans to buy the remaining shares in Alta Copper. Nothing locally on the economic front but Japanese factory sentiment improved opening the way to a rate rise this week. China announced its weakest retail numbers since Covid. Asian markets eased on US falls, Japan down 1.4%, HK down 0.9% and China off 0.2%.US futures were better, Dow up 160 and Nasdaq up 52.10-year yields steady at 4.72%.Want to invest with Marcus Today? Our MT20 portfolio is designed for investors seeking exposure to our strategy while we do the hard work for you. If you're looking for personal financial advice, our friends at Clime Investment Management can help. Their team of licensed advisers operates across most states, offering tailored financial planning services.  Why not sign up for a free trial? Gain access to expert insights, research, and analysis to become a better investor.

Die Schalker Knappenschmiede läuft heiß! Was ist das Erfolgsrezept? Und welche Rolle spielt Trainer Miron Muslic dabei? kicker-Reporter Toni Lieto klärt auf. Außerdem: Nicht alles ist so, wie es scheint! Der SC Freiburg ist in der Europa League noch ungeschlagen und steht in der Liga knapp in der oberen Tabellenhälfte. Warum die Situation trügerisch ist, erklärt kicker-Reporter Carsten Schröter-Lorenz.

The ASX 200 finished the week on a very firm note up 105 points to 8697(1.2%). Up 0.7% for the week. Across the board gains, with banks surging as CBA rose 2.1% and NAB up 1.8% after its AGM. The Big Bank Basket rose to $272.70 (+1.8%). Other financials also did well, MQG bouncing 2.7% and insurers too better. QBE and SUN up over 1%. REITs bounced, GMG up 0.8% and VCX up 2.4% with healthcare too also doing well, CSL rallying 2.9% with SIG up 1.4%. Industrials better but not flying. Retail saw some shoppers out and about, JBH up 2.7% and MYR up 4.4% with losses in LOV and TPW continuing. Tech remained a sub-optimal place to be, TNE down 1.6% with XRO continuing to fall, down another 0.5% with the All-Tech Index off 0.2%.Resources again was the place to be. Gold miners soared as brokers started to amend forecasts for metal prices higher as 2026 comes into view. NST up 2.9%, GMD up 7.6% and NEM rising 5.7%. BHP and RIO also strong on copper exposure, and uranium stocks gained ground. PDN up 4.8% and DYL rising 4.9%. Lithium stocks were a little depressed.In corporate news, former ANZ CEO is suing the bank for his lost $13.5m bonus. ASB dropped 3% on news that Jim Chalmers will allow Hanwha to increase its stake to near 20%. 4DX jumped 8.8% on an options deal and BMC Minerals debuted.Nothing on the economic front.Asian markets pushed higher, Japan up 1.7% with HK up 1.4% and China up 0.1%. Want to invest with Marcus Today? Our MT20 portfolio is designed for investors seeking exposure to our strategy while we do the hard work for you. If you're looking for personal financial advice, our friends at Clime Investment Management can help. Their team of licensed advisers operates across most states, offering tailored financial planning services.  Why not sign up for a free trial? Gain access to expert insights, research, and analysis to become a better investor.

The ASX 200 started in fine form after the Fed rate cut, but finished up only 13 points to 8592 (0.2%) as enthusiasm waned after the jobs data and US futures losses. A mixed picture across the market, CBA fell 0.7% as the other three rose, the Big Bank Basket unchanged at $267.77. MQG bounced 1.4% and other financials mixed. Healthcare stumbled into casualty, CSL dropped 1.6%, RMD down 2.3% and TLX dropped 2.1%. Retails also under pressure again, JBH off 1.5% and APE dipping 3.9%. PMV fell hard too off 5.2%. Tech remained under a cloud, WTC down 2.2% and XRO falling another 1.3% with 360 off 2.2%. The All-Tech Index fell another 1.4%. REITs made up some lost ground as bond yields fell on jobs data.In resources, iron ore miners pushed higher, FMG up 0.4% and RIO up 1.8%, with BHP up 1.3%. Gold miners were mixed, RMS rose 6.7% on broker comments, NEM also doing well, up 2.1%. Lithium stocks, a little depressed, and rare earths under pressure again. LYC down 0.9% and ARU off 8.2% as a large block trade went through the market. Uranium stocks slightly positive.In corporate news, IAG fell 1.2% after the ACCC knocked back its RAC QLD acquisition. AMP settled a class action and rose 1.1% with ORG up 0.4% on further expansion at Eraring. On the economic front, the jobs data came in below expectations although the headline rate at 4.3% remained unchanged.Meanwhile in Asia, Japan down 0.8%, HK flat and China down 0.6%. 10-year yields dropped to 4.72%. Nasdaq futures down 1.2%. Dow down 0.5% on Oracle. European markets set to open weaker.Want to invest with Marcus Today? Our MT20 portfolio is designed for investors seeking exposure to our strategy while we do the hard work for you. If you're looking for personal financial advice, our friends at Clime Investment Management can help. Their team of licensed advisers operates across most states, offering tailored financial planning services.  Why not sign up for a free trial? Gain access to expert insights, research, and analysis to become a better investor.

The ASX 200 wandered around again today, waiting for the Fed, closing down 7 points to 8579 (0.1%). Banks eased back slightly, CBA down 0.5% and the Big Bank Basket fell to $267.79 (0.4%). MQG sliding another 0.7% again with other financials easier. Insurers came back to earth, with QBE down 0.4% and IAG off 1.0%. Industrials were flat, retailers fell, APE down 2.3% and JBH off 2.3% with TPW continuing to slide, off another 3.0%. WES was a bright spot up 0.7%, maybe lithium exposure! Healthcare eased back too, CSL down 0.1% and COH off 2.5%. Tech fell yet again, WTC down 1.9% and XRO sliding further, TNE off another 1.3%. Interest rate sensitive stocks under pressure. QAN down 0.8% and TCL off 1.3%.In resources, iron ore stocks picked up, BHP up 0.5% and FMG up another 0.9%. Gold miners up as RMS announced a $250m buyback. NST up 5.1% and EVN up 4.5%. Silver stocks also having a good run. Oil and gas fell and uranium stocks rose slightly.In corporate news, SBM up 10.9%, it secured a strategic partner and funding for Simberi, DRO popped 16.2% on a LW article. 4DX jumped 6.0% on a new order in the US. GQG unchanged on FUM data.On the economic front, we had Chinese CPI slightly higher than expected.Meanwhile in Asia, Japan down 0.1%, HK down 0.5% and China down 0.8%.10-year yields higher at 4.80%.US Futures – Dow down 4 and Nasdaq down 28.Want to invest with Marcus Today? Our MT20 portfolio is designed for investors seeking exposure to our strategy while we do the hard work for you. If you're looking for personal financial advice, our friends at Clime Investment Management can help. Their team of licensed advisers operates across most states, offering tailored financial planning services.  Why not sign up for a free trial? Gain access to expert insights, research, and analysis to become a better investor.

Der Windpark in Lahnau sorgt weiter für Diskussion, die Haushaltsdebatte für 2026 im Herborner Stadt-Parlament entwickelt sich zu einem Grundsatzstreit und Anti-AfD-Demonstrationen in Gießen sorgen für Diskussionsbedarf zur Pressefreiheit. Das und mehr heute im Podcast. Alle Hintergründe zu den Nachrichten des Tages finden Sie hier: https://www.mittelhessen.de/lokales/lahn-dill-kreis/lahnau/windpark-in-lahnau-was-dafuer-und-was-dagegen-spricht-5211637 https://www.mittelhessen.de/lokales/lahn-dill-kreis/herborn/grosse-sorgen-herborner-warnen-vor-kollaps-der-kommunen-5222615 https://www.mittelhessen.de/lokales/kreis-marburg-biedenkopf/marburg/kuendigung-oder-transfer-so-geht-es-weiter-bei-csl-marburg-5218958 https://www.mittelhessen.de/lokales/kreis-giessen/giessen/journalisten-verband-kritisiert-polizeieinsatz-in-giessen-minister-will-reden-5235196 https://www.mittelhessen.de/wirtschaft/wirtschaft-deutschland/gender-pay-gap-frauen-holen-bei-der-rente-kraeftig-auf-5232743 Ein Angebot der VRM.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of compelling advancements and challenges that are shaping this dynamic industry.Pfizer has recently unveiled phase 3 results for its hemophilia drug Hympavzi, positioning it as a formidable competitor against Sanofi's Qfitlia and Novo Nordisk's Alhemo. The data suggests Hympavzi offers robust efficacy, potentially revolutionizing hemophilia treatment and enhancing patient outcomes significantly. This development is not just about competition; it represents a critical stride forward in patient care for those affected by this debilitating condition.UCB plans to seek regulatory approval for Fintepla to treat an additional epileptic disorder following positive phase 3 trial results in patients with CDKL5 deficiency disorder. This decision reflects promising results and could offer new hope to patients with limited treatment options, further cementing Fintepla's position in epilepsy management.Gene therapy continues to shine with CSL's Hemgenix demonstrating sustained long-term benefits. After five years of follow-up, a single dose has reduced annualized bleeding rates by an impressive 90% in hemophilia B patients within the Hope-B study. Such long-term efficacy highlights gene therapy's transformative potential, offering lasting improvements in quality of life for patients with genetic disorders.Regulatory frameworks are also evolving, as evidenced by the CDC's Advisory Committee on Immunization Practices (ACIP) voting to modify hepatitis B vaccine guidance for newborns. This decision advocates an individualized approach, sparking debate over vaccination strategies, which reflects the complexities and delicate balance required in public health policies today.Regeneron is making strides to simplify treatment regimens for T-cell engagers Lynozyfic and Ordspono. By reducing regimen complexity, they aim to improve patient compliance and expand access, thus enhancing the potential impact on cancer care—a crucial step toward broader therapeutic accessibility.In an effort to address cost barriers and stimulate domestic production of generics, Mark Cuban has proposed lowering FDA fees. This proposal highlights ongoing discussions around regulatory reforms needed to boost generics manufacturing in the United States. Such initiatives align with broader industry goals of increasing access to affordable medications.Despite these advancements, industry insiders have expressed concerns about "unprecedented turmoil" within the FDA. These challenges underscore the critical role of stable leadership in maintaining public trust and ensuring effective regulation amidst rapid scientific progress.Obesity treatments are gaining significant attention as companies like Wave Life Sciences and Structure Therapeutics report promising data, capturing increased investor interest. This trend underscores a growing focus on innovative pharmacological approaches to address obesity—a complex, multifactorial condition that affects millions globally.The strategic landscape of cancer diagnostics is also evolving, as evidenced by Natera's acquisition of Foresight Diagnostics. This deal underscores ongoing industry consolidation efforts aimed at enhancing technological capabilities and expanding market presence—a testament to the critical role diagnostics play in comprehensive cancer care strategies.As we observe these developments, it's clear that scientific innovation coupled with strategic regulatory maneuvers is shaping the future of healthcare. These advancements offer profound implications for patient care, providing new hope through advanced therapies while highlighting the importance of effective regulation and strategic partnerships.Precision medicine continues to extend beyond oncology into fields like cardiometabolic and neSupport the show

The ASX 200 fell 39 points to 8586 (0.5%) after the RBA kept rates on hold as forecast. The index was down a similar amount before the 2.30pm announcement. Banks drifted lower, CBA down 0.6% and WBC off 0.6% with insurers staging a modest recovery, QBE up 1.2% and MPL rising 2.7%. MQG dropped another 0.9% with PNI falling 1.1%. REITs mixed, GMG down % with the rest of the sector better. Healthcare eased, CSL down 2.0% and RMD falling 2.3%. Retail stocks fell on the rates news, JBH off 1.9% and APE dropping 2.2% as SUL fell in sympathy with BAP, down 21.3% on another nasty trading update. Telcos slid lower, TLS down 0.6% and TPG with some issues fell 1.6%. Tech once again on the nose, XRO off 0.7% and TNE down 1.6% with 360 falling hard.In resources, iron ore stocks firmed, FMG up 1.7% and RIO flat. Gold miners drifted lower, PRU off 1.5% and NST falling %. Oil and gas stocks eased, uranium mixed, PDN and DYL to the good, LOT down to the bad. Lithium stocks holding, up but rare earths sliding back to earth.In corporate news, LTR dropped 2.3% on a new offtake deal, WAF fell 0.7% on drilling results.On the economic front, the RBA left rates unchanged. The board does not seem to be in a hurry to raise them either.Meanwhile in Asia, Japan up 0.2%, HK down 0.8% and China down 0.1%.10-year yields higher at 4.75%.US Futures – DJ up 9 points and Nasdaq up 10.Want to invest with Marcus Today? Our MT20 portfolio is designed for investors seeking exposure to our strategy while we do the hard work for you. If you're looking for personal financial advice, our friends at Clime Investment Management can help. Their team of licensed advisers operates across most states, offering tailored financial planning services.  Why not sign up for a free trial? Gain access to expert insights, research, and analysis to become a better investor.

In this interview, Sarah sits down with Steven, a longtime UX leader who spent 17 years at the same digital agency before an unexpected layoff forced him to re-evaluate everything. With no portfolio, no updated resume, and low confidence, Steven joined Career Strategy Lab, and everything changed.Today, Steven is thriving as a fractional product design director, long-term contractor, and consultant helping companies elevate their UX teams and integrate AI into their workflows. In this conversation, he shares how Career Stratgegy Lab's UX job search accelerator helped him rebuild his confidence, tell a clear story about 20+ years of experience, streamline his job search, and even reinvent himself as a business owner.Whether you're mid-career, coming out of a layoff, or curious about consulting, Steven's story is a grounding reminder that clarity, strategy, and community can completely change your UX career trajectory.What You'll Learn in This Episode:✔️ How Steven went from 25% confidence to 80% confidence in his job search✔️ The myth he had to unlearn: your portfolio is not the first step✔️ Why clarity + foundational work = faster, less stressful job search✔️ How CSL's community accelerated his progress and kept him motivated✔️ The mindset shift that helped him stop applying blindly to jobs✔️ How he now uses CSL's frameworks to land consulting and contract roles✔️ Why your “career operating system” needs ongoing updates✔️ How knowing your values helps you choose the right opportunitiesTimestamps:00:00 Introduction to Sarah Doody and Career Strategy Lab00:38 Episode Overview and Open House Context01:26 Sarah Doody's Background and UX Career Coaching02:31 Steven's Journey and Career Strategy Lab Experience04:13 Building Confidence and Telling Your Story06:25 The Power of Community and Networking09:55 Mindset Shifts and Career Value Criteria13:03 Freelance and Consulting Success Tips16:01 Final Thoughts and Advice18:53 Conclusion and Next Steps

The ASX's headline yield has slipped, but dividend income is still on offer if investors know where to look. In this episode of The Rules of Investing, IML's Dr Michael O'Neill explains the dividend outlook, shares five ASX income picks, and outlines the mistake investors are making on rates and valuation risk. *Correction - in the podcast Michael mistakenly said the yield on CSL is 4% when it is actually closer to 3% based on 1-year forward estimates from brokers. 

We love to hear from our listeners. Send us a message.On episode 117, Host Erin Harris welcomes Paul Perreault, Strategic Advisor, Board Member and former CEO of CSL, who shares insights from his decade leading the company through global expansion and the COVID-19 pandemic. Perreault highlights the importance of patient-centered culture, strategic focus, and adaptive leadership for cell and gene therapy innovators. He offers practical advice on building a values-driven culture that connects employees to patients, the importance of focusing on core competencies to attract capital, and the necessity of continuous leadership development, even advocating for mentorship and emotional intelligence as growth drivers in fast-evolving organizations.Subscribe to the podcast!Apple | Spotify | YouTube Visit my website: Cell & Gene Connect with me on LinkedIn

In this special coach takeover episode Erin, one of the coaches inside Career Strategy Lab's UX job search accelerator, breaks down the three most important things UX and product professionals should focus on in Q4 to set themselves up to get hired in Q1 of 2026.Whether you're feeling stuck, doubting your materials, overwhelmed by your portfolio, or unsure what support you actually need, this episode gives you a strategic and human approach to moving your job search forward.Erin shares what she and the CSL team are seeing every week while reviewing resumes, portfolios, and LinkedIn profiles—and the biggest patterns that determine whether someone gains traction or stays stuck in place.What You'll Learn in This Episode:✔️ Why you must rethink who you're getting job search feedback from✔️ How inaccurate feedback erodes confidence—and what to do instead✔️ The “back to basics” portfolio reset that outperforms flashy trends✔️ Why hiring managers want clarity over cleverness (and no, you don't need animations)✔️ How to build trust through your case study storytelling✔️ How to determine what level of support you actually need—structure, community, coaching, or therapy✔️ Why Q4 is the perfect time to prepare for Q1 hiring surgesTimestamps:00:00 Introduction to Career Strategy Lab00:38 Three Key Strategies for Getting Hired in Q1 202601:11 Assessing Feedback on Your Career Materials05:50 Back to Basics: Improving Your Portfolio09:19 Getting the Support You Need16:04 Recap and Final Thoughts18:49 Conclusion and Additional Resources19:32 Special Message for Job Seekers

Black Friday panic, Christmas chaos… and a derivatives-led global equity sell-off. In this episode of Talk Money To Me, Candice and Felicity zoom out from the noise and share six major investment themes set to shape portfolios in 2026 plus the ETFs, sectors and stocks they're watching right now.Recorded on 25 November 2025 following a sharp but non-fundamental global equity pullback driven by CTAs, futures activity and a VIX spike, the pair break down why retail investors have been buying the dip, not selling it and why the medium-term setup for equities remains constructive.They then reveal their 2026 Playbook, covering:⭐ Theme 1 – Mid-Duration Fixed Income & Floating RatesWhy the 3–5 year part of the curve, senior bank notes, floating-rate notes and diversified bond ETFs (like MQSD) are compelling defensive anchors heading into an uncertain rate environment.

Applied to 50+ UX or Product jobs & still no interviews or offers? Get UX job search help.Welcome to the Career Strategy Podcast with Sarah Doody, a UX Designer & UX Researcher with 20 years of experience who founded the UX job search accelerator, Career Strategy Lab. She's been doing UX career coaching since 2017.Follow Sarah on: LinkedIn | YouTube | InstagramTransitioning from academia to UX can be daunting, but Ellen's story proves it's possible. After 17 years as a professor, Ellen pivoted to a Senior Content Designer role at TD Bank, with Career Strategy Lab providing the strategy, clarity, and confidence she needed to make the leap.In this episode, Ellen shares how CSL helped her reframe her experience, confidently communicate her transferable skills, and land her UX role—all while navigating the challenges of switching careers.What You'll Learn in This Episode:✔️ How Ellen navigated the shift from academia to UX✔️ Why confidence was her biggest challenge and how CSL helped her overcome it✔️ The importance of understanding how to communicate transferable skills✔️ How she used the Compass Statement to connect her past experience to her new career✔️ The value of having a portfolio and LinkedIn that clearly reflect your skills✔️ Ellen's tips on standing out during the job search with an authentic, tailored approachTimestamps:00:00 Introduction to Sarah Doody and Career Strategy Lab00:38 Episode Overview and Open House Context01:25 Sarah Doody's UX Career Coaching Journey02:29 Alan's Career Transition Story03:39 Building Confidence and Skills with CSL08:33 Mindset Shifts and Life Lessons10:47 Practical Tips for Job Seekers12:40 Final Thoughts and Encouragement14:04 Podcast Outro and Additional Resources14:44 Special Message for Job Seekers ⭐ Support the show! Leave a rating on Spotify or a review on Apple Podcasts to help more UX professionals find this podcast.

Send us a textGood morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the dynamic landscape of the industry, exploring significant scientific advancements, regulatory changes, clinical trial outcomes, and strategic investments that are shaping the future of healthcare.Starting with strategic investments, Regeneron is making a bold move with a $2 billion investment to transform a former magazine factory in Saratoga Springs, New York, into a state-of-the-art drug manufacturing plant. This investment reflects a broader industry trend towards enhancing domestic manufacturing capabilities to ensure supply chain resilience. Similarly, CSL is channeling $1.5 billion into U.S. plasma-based manufacturing over the next five years. These investments are critical as plasma-derived therapies continue to play a vital role in treating various conditions, necessitating robust manufacturing infrastructure to meet growing demand.In clinical research, Merck's Winrevair has shown promising results in a proof-of-concept study for heart failure patients. This advancement highlights ongoing efforts to address one of the leading causes of morbidity and mortality worldwide—heart failure. The study paves the way for further exploration of activin signaling inhibitors in cardiovascular therapies.On the regulatory front, Eli Lilly has expanded its market reach with the approval of its Alzheimer's medication for distribution in India. This milestone represents progress in tackling the global Alzheimer's disease burden, an ailment that presents significant challenges to healthcare systems worldwide.The FDA's recent critique of AstraZeneca's Farxiga advertisement underscores the importance of accuracy in pharmaceutical marketing. The agency's concerns about potential misleading impressions emphasize ongoing regulatory vigilance to align marketing practices with approved therapeutic uses and ensure patient safety.Shifting to business strategies, Zymeworks' transition towards becoming a 'royalty-driven organization' marks an evolution in biotech business models. By leveraging successful licensing frameworks, Zymeworks aims to enhance revenue streams while focusing on innovation without the traditional constraints of direct commercialization.In cardiovascular therapeutics, Cytokinetics is positioning itself strategically by funding a heart registry, signaling an intensifying competitive landscape as companies vie for leadership in this critical area of healthcare.Roche's development of giredestrant, an oral selective estrogen receptor degrader (SERD), has achieved success in a phase 3 adjuvant breast cancer trial. This positions Roche to capture an unoccupied niche within the competitive breast cancer treatment market and highlights a trend towards targeted therapies with potentially significant patient outcomes.Addressing side effects associated with GLP-1 receptor agonists, Vanda Pharmaceuticals is making strides with tradipitant to mitigate nausea and vomiting induced by Wegovy. As GLP-1 agonists gain traction for their metabolic benefits, adjunct therapies addressing side effects are becoming increasingly pertinent.In digital health initiatives, Humana's collaboration with Epic aims to automate insurance verification and patient check-ins, aligning with federal interoperability goals. This represents a broader industry shift towards digital solutions designed to streamline administrative processes and enhance patient experience.Meanwhile, Lonza's expansion at its Stein facility in Switzerland underscores ongoing capacity-building efforts among contract development and manufacturing organizations (CDMOs). Such expansions are crucial as they provide biopharmaceutical companies with the neSupport the show

Wall Street extended its losing streak, with the S&P 500 falling for a fourth straight day as investors braced for Nvidia’s high-stakes AI results. In company news, Microsoft and Nvidia announced plans to invest up to $15 billion in Anthropic, while Home Depot slipped after cutting its forecast on weaker demand. In the commodities market, oil prices steadied as traders weighed the impact of Russian sanctions. Back home, Aussie shares are expected to hover near five-month lows on Wednesday ahead of wages data, while CSL plans to invest $1.5 billion in US drug manufacturing. The content in this podcast is prepared, approved and distributed in Australia by Commonwealth Securities Limited ABN 60 067 254 399 AFSL 238814. The information does not take into account your objectives, financial situation or needs. Consider the appropriateness of the information before acting and if necessary, seek appropriate professional advice.See omnystudio.com/listener for privacy information.

In this episode, Sarah sits down with Phoenix, a Career Strategy Lab (CSL) member who shares what it's like to be in the middle of their UX job search transformation.Phoenix opens up about the identity crisis that came from trying to be what companies wanted and how shifting toward a product-thinking approach—treating their career like a system—led to clarity, confidence, and traction. This is a must-listen for any UX or product professional feeling stuck, unfocused, or uncertain about how to move forward in today's job market.You'll hear Phoenix share the exact moment things started to click, the biggest mindset shifts since joining CSL, and how things like a simple resume rewrite not only clarified their value—but also unlocked a potential $20K salary bump.Whether you're pivoting into UX, climbing toward leadership, or simply tired of second-guessing yourself, Phoenix's story will help you see what's possible when you stop trying to be someone you're not and start owning what you bring to the table.What You'll Learn in This Episode:✔️ How Phoenix went from feeling irrelevant to in control of their UX career✔️ Why “conforming” to what employers want actually backfires—and what to do instead✔️ The power of the compass statement and how it transforms resumes, portfolios, and interviews✔️ How systems thinking applies to both UX and job search strategy✔️ The emotional journey of building a personal brand that reflects your true strengths✔️ Why clarity is more powerful than pep talks when it comes to confidenceTimestamps:00:00 Introduction to Career Strategy Lab00:38 Episode Overview and Open House Context01:22 Q&A with Phoenix: UX Job Search Insights03:59 Phoenix's Journey: From Uncertainty to Clarity07:33 The Power of a Strong Resume and Compass Statement20:04 Emotional Impact and Personal Growth24:19 Advice for Job Seekers and Final Thoughts

Health editor Michael Smith discusses CSL’s remarkable story, why investors have lost faith in the healthcare giant and what Trump has to do with it. This podcast is sponsored by Aussie Broadband Further reading: How CSL went from 'bloated bureaucracy' to $145b global behemothWhen Brian McNamee took on the top job at Commonwealth Serum Laboratories, the government-run entity was barely worth the land it was built on.McNamee vows to stay CSL chairman despite growing investor disquietThe pharmaceutical giant has avoided a board spill, but a market bloodbath arising from declining US vaccine rates has investors seething.‘We have to fix this’: Brian McNamee on turning around CSLCSL was once a market darling, now it’s out of favour and pressure is on board and management to convince sceptical investors of a plan to restructure the business.See omnystudio.com/listener for privacy information.

The ASX200 slid 0.9% (81 points) to a five‑week low after the RBA left rates at 3.6%. Hotter‑than‑forecast inflation curbed cut hopes. All sectors except healthcare fell, with Westpac the sole bank up 1.5%. City Chic rose 7.5% after a solid ANZ update, while CSL remains down 40% YTD. Focus now shifts to inflation data on 26 Nov and upcoming employment and earnings releases. The content in this podcast is prepared, approved and distributed in Australia by Commonwealth Securities Limited ABN 60 067 254 399 AFSL 238814. The information does not take into account your objectives, financial situation or needs. Consider the appropriateness of the information before acting and if necessary, seek appropriate professional advice.See omnystudio.com/listener for privacy information.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a dynamic landscape of scientific breakthroughs, regulatory shifts, and strategic maneuvers reshaping the industry.BioMarin's recent decision to divest from its hemophilia A gene therapy, Roctavian, has garnered significant attention. Despite being the sole approved gene therapy for hemophilia A, Roctavian has struggled with sales since its launch two years ago. This move underscores the complex challenges in commercializing gene therapies, highlighting that even groundbreaking treatments can face hurdles in market penetration. It reflects broader implications for the commercialization strategies of innovative therapies and emphasizes that market acceptance is as crucial as clinical efficacy.In manufacturing and regulatory affairs, Regeneron is navigating hurdles with its Eylea HD due to persistent manufacturing issues. The FDA's complete response letter points to ongoing problems at a Novo Nordisk plant. This situation illustrates the critical role of manufacturing standards in securing regulatory approvals and ensuring consistent product availability. Regeneron's efforts to seek alternative manufacturing solutions emphasize the importance of compliance and quality assurance in the pharmaceutical landscape.Roche is advancing its kidney disease portfolio with a Phase 3 trial success for Gazyva against idiopathic nephrotic syndrome. Building on previous approvals for lupus nephritis, this achievement underscores Roche's strategic focus on expanding indications for existing biologics. It highlights the value of lifecycle management strategies in maximizing therapeutic potentials and extending the reach of established drugs.A significant shift in pharmacy benefit management is underway as Cigna's Evernorth division moves away from PBM rebates through Express Scripts. This transition towards a rebate-free model may influence industry-wide practices, addressing growing scrutiny over rebate structures criticized for their lack of transparency and their impact on drug pricing.CSL's decision to delay the spinoff of its flu vaccine unit amid declining U.S. immunization rates illustrates market challenges in vaccine uptake. The anticipated drop, particularly among older populations, raises public health concerns and underscores the necessity for enhanced outreach and education to improve immunization coverage.On the investment front, AbbVie, Regeneron, and Sanofi have collectively invested $80 million in ZAG Bio's Series A funding round. This company is developing thymus-targeted medicines for autoimmune diseases, reflecting continued interest in novel therapeutic approaches addressing unmet medical needs within the biotech space.Catalent's rebranding initiative signifies a strategic effort to align corporate identity with mission-driven objectives, emphasizing "missions that matter" as it approaches an anniversary milestone with Novo Nordisk's acquisition. Such rebranding efforts are critical for differentiating service offerings and reinforcing corporate values within competitive markets.The competitive landscape within diabetes and obesity treatment markets is experiencing a potential paradigm shift following the results from Innovent and Eli Lilly's Phase 3 trial of mazdutide. This dual GLP-1/glucagon receptor agonist outperformed Novo Nordisk's semaglutide, offering improved outcomes in weight reduction and glycemic control. Mazdutide's dual mechanism could redefine treatment protocols, offering patients enhanced therapeutic benefits.MapLight Therapeutics has successfully raised $250 million through an IPO to advance its schizophrenia treatment candidate, Cobenfy. This funding supports further clinical development and potential commercialization efforts, reflecting investor confidence in innovative neurologSupport the show

The ASX200 slipped almost 1% to its worst daily drop since 3 Sept, spurred by September CPI showing headline 3.2% and core at 3%, topping the RBA’s target. Markets now see only a 5% chance of a rate cut at the Melbourne Cup meeting. Energy and gold miners led modest gains, while financials and CSL fell sharply. The content in this podcast is prepared, approved and distributed in Australia by Commonwealth Securities Limited ABN 60 067 254 399 AFSL 238814. The information does not take into account your objectives, financial situation or needs. Consider the appropriateness of the information before acting and if necessary, seek appropriate professional advice.See omnystudio.com/listener for privacy information.

SBS Finance Editor Ricardo Gonçalves speaks with Australia's Special Envoy to Southeast Asia Nicholas Moore to find out how regional leaders feel about doing business with Australians as he attends the ASEAN summit; plus Michael Jenneke from UBS Management takes a look at the day's sharemarket action as CSL and Wisetech shares crash.

The ASX200 fell about 0.5% today, erasing Monday’s gains, but stays up 2% for October and just 1% below a record high. Financials rallied, with the big four banks hitting record levels, while CSL and WiseTech drove the decline, dropping 16% and 15% respectively. Look ahead to tomorrow’s CPI release and the RBA’s likely rate cut on Melbourne Cup Day. The content in this podcast is prepared, approved and distributed in Australia by Commonwealth Securities Limited ABN 60 067 254 399 AFSL 238814. The information does not take into account your objectives, financial situation or needs. Consider the appropriateness of the information before acting and if necessary, seek appropriate professional advice.See omnystudio.com/listener for privacy information.

Police & ASIC have raided Wisetech Global offices, while CSL finds a tough crowd at its AGM.See omnystudio.com/listener for privacy information.

Ep. 335 Eternal Light - Rev. Mary Mitchell From the Sunday Service at the Center for Spiritual Living in Redding on 10-26-25

Ep. 334 Inner Knowing - Rev. Melissa Harris From the Sunday Service at the Center for Spiritual Living in Redding on 10-19-25

After being laid off and earning a Master's degree in UX, Melp still wasn't landing UX job interviews. What changed? She stopped applying to everything and started thinking strategically.In this Q&A from a Career Strategy Lab Open House, Sarah Doody talks with Melp, a UX researcher turned product manager, about the ups and downs of her UX job search journey. Despite years of experience, a Masters degree in UX from the University of Michigan, and hundreds of UX job applications, Melp wasn't getting traction, until she joined Career Strategy Lab.You'll hear how she slowed down to get clear, challenged the narrative that she was “difficult to work with,” and started positioning herself as a strategic asset (not a liability). Her confidence began to rebuild, not because of a new certification, but because she finally saw her work for what it was: valuable.What You'll Learn in This Episode:✔️ Why Melp chose strategy over hustle in her UX job search✔️ How the Career Compass Sprint helped her identify what she really wanted✔️ The mindset shift from “I'm difficult” to “I'm a high-impact team member”✔️ Why she stopped over-preparing and started owning her story✔️ How CSL's “minimum viable portfolio” mindset freed her up to move forward faster✔️ The difference between traditional career support and CSL's strategic, in-depth processTimestamps:00:00 Introduction to Career Strategy Lab02:14 Melp's Career Journey and Challenges03:39 The Importance of Finding the Right Job05:25 Deep Dive into Career Compass Sprint07:02 Confidence and Self-Discovery09:02 The Diva Mindset and Environment Fit17:02 CSL's Unique Approach and In-Depth Process22:18 Final Thoughts and Advice for Job Seekers24:13 Conclusion and Podcast Outro24:53 Special Message for Job Seekers

Ep. 333 Reverence for the Earth - Rev. Dr. Andrea Asebedo From the Sunday Service at the Center for Spiritual Living in Redding on 10-12-25

Ep. 332 Inner Illumination - Rev. Sue MillerBorn From the Sunday Service at the Center for Spiritual Living in Redding on 10-5-25

The Aussie share market finished the week strongly, up 0.5% on Friday and 2.3% across the week, marking its best weekly performance since early May. Tech stocks led gains with Live360 and Block, Inc. among the top performers, while energy lagged as oil prices slipped to four-month lows. Eagers Automotive surged nearly 18% after announcing a major Canadian acquisition, while DroneShield climbed 50% for the week. Dividend payouts from CSL, A2 Milk, Origin, Domino’s and others also put extra cash in investors’ pockets, while attention now turns to US earnings season, a New Zealand rate decision and uncertainty from the US government shutdown. The content in this podcast is prepared, approved and distributed in Australia by Commonwealth Securities Limited ABN 60 067 254 399 AFSL 238814. The information does not take into account your objectives, financial situation or needs. Consider the appropriateness of the information before acting and if necessary, seek appropriate professional advice.See omnystudio.com/listener for privacy information.

The ASX200 rose 1.2% to a one-month high, edging closer to 9,000 points in a broad rally led by gold, banks and healthcare. Gold miners surged as prices hit fresh records near US$3,900 an ounce, while CSL bounced almost 4% and the big four banks all advanced. Globally, investors weighed the US government shutdown, weaker jobs data and strong US pharma gains, while dividend season picked up with payouts from Breville, Seek and Treasury Wines. The content in this podcast is prepared, approved and distributed in Australia by Commonwealth Securities Limited ABN 60 067 254 399 AFSL 238814. The information does not take into account your objectives, financial situation or needs. Consider the appropriateness of the information before acting and if necessary, seek appropriate professional advice.See omnystudio.com/listener for privacy information.

Ep. 331 Hope and Resilience - Rev. Sue MillerBorn From the Sunday Service at the Center for Spiritual Living in Redding on 9-28-25

Ep. 330 Listening to Spirit - Rev. Sue MillerBorn From the Sunday Service at the Center for Spiritual Living in Redding on 9-21-25

Applied to 50+ UX or Product jobs & still no interviews or offers? Get UX job search help.Welcome to the Career Strategy Podcast with Sarah Doody, a UX Designer & UX Researcher with 20 years of experience who founded the UX job search accelerator, Career Strategy Lab. She's been doing UX career coaching since 2017.Follow Sarah on: LinkedIn | YouTube | InstagramAfter 18 months of job searching with no results, Mariah was out of steam and questioning everything—until she joined Career Strategy Lab.In this Open House conversation, Sarah talks with Mariah, a UX researcher and experience strategist with a background in customer support and consulting. Mariah came to CSL after burning out from a year and a half of job searching while trying to relocate to Copenhagen. In this honest episode, she shares what finally helped her stop spinning, reconnect with herself, and gain the clarity, confidence, and support she'd been missing.Whether you're new to UX or deep in burnout, Mariah's story will remind you that it's not too late—and you don't have to figure it out alone.What You'll Learn in This Episode:✔️ What job searching for 18+ months taught Mariah about burnout and boundaries✔️ Why trying to “game the system” kept her stuck and exhausted✔️ How the Compass Sprint reconnected her to her voice, identity, and strengths✔️ Why the mindset calls inside CSL helped her finally feel like herself again✔️ How to balance personal and professional identity in your job search✔️ Her advice for perfectionists and overthinkers: take action, even when it's messyTimestamps:02:27 Mariah's Background and Career Journey04:21 Joining Career Strategy Lab: Initial Experiences08:09 Impact of Mindset Calls11:50 Tangible Actions and Career Roadmap18:43 Final Advice and Closing Remarks21:22 Podcast Outro and Additional Resources22:03 Special Message for Job Seekers⭐ Support the show! Leave a rating on Spotify or a review on Apple Podcasts to help more UX professionals find this podcast.

Ep. 329 What is Calling You? - Rev. Sue MillerBorn From the Sunday Service at the Center for Spiritual Living in Redding on 9-14-25

With Pfizer discontinuing Beqvez and BioMarin scaling back the commercial focus of Roctavian, the curative promise of hemophilia gene therapies is tempered by significant barriers that discourage widespread adoption. In this week’s episode of “The Top Line,” Fierce Pharma’s Zoey Becker speaks with Glenn Pierce, M.D., Ph.D., vice president of medical at the World Federation of Hemophilia, about the complexities behind these innovative therapies and the multifaceted reasons for their slow uptake. Pierce discusses the competitiveness of the current hemophilia gene therapy market, why Pfizer’s product couldn’t keep up, and the patient populations that risk being left behind. To learn more about the topics in this episode: As Pfizer backs out of hemophilia gene therapy space, CSL hopes Hemgenix is here to stay Pfizer discontinues hemophilia treatment Beqvez, emptying its gene therapy portfolio BioMarin downsizes Roctavian efforts but keeps hemophilia gene therapy for 3 markets See omnystudio.com/listener for privacy information.

CSL 裁员3000人，而公司利润明明在上涨。 这是否由AI 引发？普通人如何保住饭碗？Morgans 亚洲业务主管深度解析，点击收听，并欢迎您在SBS中文社交媒体平台留言，表达您的观点。

What do seminary school, a dairy burn room, and running a global biotech powerhouse have in common? Paul Perreault. In this episode of The Authority Company Podcast, host Joe Pardavila sits down with Paul Perreault, former CEO of CSL and author of The Detour CEO, to explore how a non-linear path shaped his values-driven approach to leadership. Paul opens up about working 80-hour weeks in a restaurant, scrubbing burnt milk, and studying to become a priest—all before leading a multi-billion dollar company. He shares why being a generalist is underrated, how to separate identity from work, and what it really means to “add value” in life and business. Whether you're navigating your own professional pivot or leading a team, Paul's insights on humility, culture, and the myth of the corporate ladder are worth the listen.

Applied to 50+ UX or Product jobs & still no interviews or offers? Get UX job search help.Welcome to the Career Strategy Podcast with Sarah Doody, a UX Designer & UX Researcher with 20 years of experience who founded the UX job search accelerator, Career Strategy Lab. She's been doing UX career coaching since 2017.Follow Sarah on: LinkedIn | YouTube | InstagramWondering how to stand out in UX without burning out? Former technical recruiter Ellie shares her story of switching into product design—and how Career Strategy Lab helped her get her confidence back.In this episode, Sarah interviews Ellie, a former technical recruiter turned UX designer, who joined Career Strategy Lab while navigating new motherhood, burnout, and the unpredictable job market. Despite landing interviews, Ellie felt stuck—and knew she needed a structured, supportive way to rebuild confidence and stand out.You'll hear how she overcame perfectionism, reframed her job search, and built career habits that now extend beyond her portfolio and into her life.What You'll Learn in This Episode:✔️ Why Ellie left tech recruiting to pursue UX—and doesn't regret it✔️ What made her say “yes” to CSL (and why she wishes she joined sooner)✔️ How the Compass Statement gave her clarity and saved her time✔️ The unexpected life shifts that came from doing the work with intention✔️ Tips for breaking perfectionism and building habits that stick✔️ What it's like to join CSL while navigating new parenthood and burnoutTimestamps:00:00 Introduction to Career Strategy Lab00:38 Episode Overview and Open House Context02:23 Meet Ellie: From Technical Recruiter to Product Designer05:19 Ellie's Career Journey and CSL Experience09:16 The Impact of Career Strategy Lab18:47 Advice and Final Thoughts21:32 Conclusion and Next Steps⭐ Support the show! Leave a rating on Spotify or a review on Apple Podcasts to help more UX professionals find this podcast.

Two years ago Mark purchased CSL. The share has not done well in that period. Mark goes through his thoughts on CSL, whether it still meets his original thesis, and evaluates whether the share deserves a place in his portfolio.You can find the full article here. A message from Mark and ShaniFor the past five years, we've released a weekly podcast to arm you with the tools to invest successfully. We've always strived to provide independent, thoughtful analysis, backed by the work of hundreds of researchers and professionals at Morningstar.We've shared our journeys with you, and you've shared back. We've listened to what you're after and created a companion for your investing journey. Invest Your Way is a book that focuses on the investor, instead of the investments. It is a guide to successful investing, with actionable insights and practical applications.The book is currently in presale which is an important time to build momentum. If anyone would like to support this project you can buy the book now. Thanks in advance!Purchase from Amazon or Purchase from BooktopiaTo submit any questions or feedback, please email mark.lamonica1@morningstar.com or leave us a voicemail to feature on the podcast here.Audio Producer and mixer: William Ton. Hosted on Acast. See acast.com/privacy for more information.

Audio roundup of selected biopharma industry content from Scrip over the business week ended August 22, 2025. In this episode: Madrigal regains MASH lead with EU Rezdiffra approval; Viking's obesity data scare investors; China assets lead GLP-1 deals; CSL and others restructure; and Indegene exec on DTP and MFN policies. https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-T77LV22VANAL5GNPCC2YUVLZBE/ This episode was produced with the help of AI text-to-voice and voice emulation tools. Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things

– RBA’s $1.2b renovation – Economic roundtable disappointment – CSL, James Hardie and Audinate hit for six – Qantas’ $90m fine and NAB’s $130m make-good – CBA’s AI SNAFUSee omnystudio.com/listener for privacy information.

Applied to 50+ UX or Product jobs & still no interviews or offers? Get UX job search help.Welcome to the Career Strategy Podcast with Sarah Doody, a UX Designer & UX Researcher with 20 years of experience who founded the UX job search accelerator, Career Strategy Lab. She's been doing UX career coaching since 2017.Follow Sarah on: LinkedIn | YouTube | InstagramLaid off and wondering if you've “missed your shot”? This story will change how you think about career momentum.In this Open House conversation, Sarah sits down with Manny, a senior UX designer who transitioned into UX after a decade in graphic design and just landed a role at Fidelity. After getting laid off and spending weeks spinning his wheels, Manny joined Career Strategy Lab to bring clarity, structure, and confidence back to his job search.In this honest and insightful conversation, Manny shares what helped him rebuild momentum, how the Compass Sprint shaped everything from his resume to interviews, and why he wishes he'd joined sooner.What You'll Learn in This Episode:✔️ How Manny landed a UX role at Fidelity after being laid off✔️ The single most valuable CSL exercise (that he didn't expect)✔️ Why clarity leads to faster progress across your materials✔️ How the Compass Statement helped him shape his story and stand out✔️ Why applying early in your job search saves you time, money, and confidence✔️ How to make the most of CSL—whether you're employed or notTimestamps:02:28 Meet Manny: A UX Designer's Journey03:51 Navigating Job Search Challenges06:16 The Impact of Career Strategy Lab12:27 Advice for UX Job Seekers14:54 Conclusion and Final Thoughts15:07 Podcast Outro and Additional Resources15:47 Special Message for Job Seekers⭐ Support the show! Leave a rating on Spotify or a review on Apple Podcasts to help more UX professionals find this podcast.

Qantas has copped a record $90 million fine for its illegal sackings of staff…and more than half of the money is going straight to the union. CSL, the Aussie biotech, is cutting almost 3000 staff globally, as part of the biggest shake-up of the last decade. Soho House, the members club, is going private again after battling in the public markets for the past 4 years. _ Learn more about iShares by BlackRock here Download the free app (App Store): http://bit.ly/FluxAppStore Download the free app (Google Play): http://bit.ly/FluxappGooglePlay Daily newsletter: https://bit.ly/fluxnewsletter Flux on Instagram: http://bit.ly/fluxinsta Flux on TikTok: https://www.tiktok.com/@flux.finance —- The content in this podcast reflects the views and opinions of the hosts, and is intended for personal and not commercial use. We do not represent or endorse the accuracy or reliability of any opinion, statement or other information provided or distributed in these episodes.__ Issued by BlackRock Investment Management (Australia) Limited ABN 13 006 165 975, AFSL 230 523. Refer to FSG available on our website. Before making any investment decisions, you should assess whether the product or service is appropriate for you and read the PDS and TMD available at blackrock.com.au.See omnystudio.com/listener for privacy information.